Showing results (1861-1870 of 2,081) with videos related to
Sort By:
Pageof 209
JCI Insight|July 19, 2016
A flexible, multilayered protein scaffold maintains the slit in between glomerular podocytesFlorian Grahammer, Christoph Wigge, Christoph Schell, et al.Cell Stem Cell|January 21, 2010
An RNAi screen identifies TRRAP as a regulator of brain tumor-initiating cell differentiationHeiko Wurdak, Shoutian Zhu, Angelica Romero, et al.Blood Advances|September 25, 2024
Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literatureCôme Bommier, Brian K Link, Brianna J Gysbers, et al.Blood Advances|April 26, 2024
Defining primary refractory large B-cell lymphomaAllison M Bock, Raphael Mwangi, Yucai Wang, et al.Biorxiv : the Preprint Server for Biology|June 9, 2020
Age-determined expression of priming protease TMPRSS2 and localization of SARS-CoV-2 infection in the lung epitheliumBryce A Schuler, A Christian Habermann, Erin J Plosa, et al.Cancer Causes & Control : CCC|May 1, 2012
Early life sun exposure, vitamin D-related gene variants, and risk of non-Hodgkin lymphomaJennifer L Kelly, Matthew T Drake, Zachary S Fredericksen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2012
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)Leo I Gordon, Fangxin Hong, Richard I Fisher, et al.Blood Cancer Journal|August 26, 2017
Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphomaS I Tracy, M J Maurer, T E Witzig, et al.JCO Oncology Practice|May 17, 2022
Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard CareSurbhi Sidana, Cristine Allmer, Melissa C Larson, et al.American Journal of Hematology|February 18, 2017
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphomaN Nora Bennani, Betsy R LaPlant, Stephen M Ansell, et al.Pageof 209